Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Research & Development (2016 - 2024)

Cytosorbents (CTSO) has disclosed Research & Development for 13 consecutive years, with $1.9 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Research & Development fell 50.62% year-over-year to $1.9 million, compared with a TTM value of $9.7 million through Sep 2024, down 35.38%, and an annual FY2023 reading of $15.7 million, up 4.03% over the prior year.
  • Research & Development was $1.9 million for Q3 2024 at Cytosorbents, up from $1.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $6.1 million in Q4 2021 and bottomed at $1.5 million in Q2 2024.
  • Average Research & Development over 5 years is $3.2 million, with a median of $3.4 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 143.07% in 2021, then plummeted 58.58% in 2024.
  • Year by year, Research & Development stood at $2.7 million in 2020, then surged by 128.51% to $6.1 million in 2021, then tumbled by 44.57% to $3.4 million in 2022, then increased by 20.42% to $4.1 million in 2023, then crashed by 54.81% to $1.9 million in 2024.
  • Business Quant data shows Research & Development for CTSO at $1.9 million in Q3 2024, $1.5 million in Q2 2024, and $2.2 million in Q1 2024.